Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme

This article was originally published in PharmAsia News

Executive Summary

AMAG Pharmaceuticals announced April 1 it would team up with Takeda Pharmaceutical to commercialize its intravenous iron drug Feraheme (ferumoxytol) outside the US. A deal was not unexpected, as AMAG has signaled since winning approval from U.S. FDA in 2009 that the best way to maximize growth of Feraheme, especially in the European Union, is with a partner with global reach

You may also be interested in...



Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership

TOKYO - Takeda, like most Japanese pharma, is hoping to counter the ongoing trend of patent expirations and yen appreciation by looking outward. Pushing beyond their comfort zones of Japan and U.S. markets, Japan's top pharma are pushing to gain ground in Europe and Asia. Similarly, these companies are looking outside of their own staff for expertise in these new regions

Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership

TOKYO - Takeda, like most Japanese pharma, is hoping to counter the ongoing trend of patent expirations and yen appreciation by looking outward. Pushing beyond their comfort zones of Japan and U.S. markets, Japan's top pharma are pushing to gain ground in Europe and Asia. Similarly, these companies are looking outside of their own staff for expertise in these new regions

Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.

Takeda is gearing up for a 2010 launch of the orphan bone cancer immunotherapy Mepact (mifamurtide) in Europe and is considering re-submitting its failed U.S. FDA application for that compound, after buying IDM Pharma for $75 million in a deal announced May 18

Related Content

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel